BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27268926)

  • 1. Electroneurography in the evaluation of oxaliplatin-induced neuropathy in colorectal cancer patients.
    Zygulska AL; Banach M; Krzemieniecki K
    Neoplasma; 2016; 63(4):617-22. PubMed ID: 27268926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.
    Kandula T; Farrar MA; Krishnan AV; Murray J; Timmins HC; Goldstein D; Lin CS; Kiernan MC; Park SB
    Muscle Nerve; 2018 Apr; 57(4):615-621. PubMed ID: 28881477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy-induced polyneuropathy symptoms and signs.
    Krøigård T; Svendsen TK; Wirenfeldt M; Schrøder HD; Qvortrup C; Pfeiffer P; Gaist D; Sindrup SH
    Eur J Neurol; 2020 Jan; 27(1):68-76. PubMed ID: 31373417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
    Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer.
    Nagata T; Fukuda KI; Tamai M; Taniguchi A; Kamiya H; Kambe K; Kamada Y; Iwata G; Yamaoka N
    Anticancer Res; 2019 Mar; 39(3):1347-1353. PubMed ID: 30842168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.
    Chen SC; Huang HP; Huang WS; Lin YC; Chu TP; Beaton RD; Jane SW
    Eur J Oncol Nurs; 2020 Dec; 49():101834. PubMed ID: 33120223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neuropathy index based on motor-sensory electroneurography (ENeG).
    Wennberg A
    Acta Neurol Scand Suppl; 1984; 100():107-11. PubMed ID: 6091391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
    Pitarokoili K; Höffken N; Lönneker N; Fisse AL; Trampe N; Gold R; Reinacher-Schick A; Yoon MS
    J Neuroimaging; 2019 Jan; 29(1):133-139. PubMed ID: 30198601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
    Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
    Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation.
    Matsumoto Y; Yoshida Y; Kiba S; Yamashiro S; Nogami H; Ohashi N; Kajitani R; Munechika T; Nagano H; Komono A; Aisu N; Yoshimatsu G; Hasegawa S
    Support Care Cancer; 2020 Nov; 28(11):5405-5410. PubMed ID: 32144582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis.
    Lu LC; Tsay SL; Chang SY; Chen CM; Liu CY
    Cancer Med; 2019 Mar; 8(3):963-971. PubMed ID: 30741481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment.
    Yigit O; Kulak Kayikci ME; Temucin CM; Sarac S; Erman M; Belgin E
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):513-520. PubMed ID: 30997533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.